TITLE

Building an understanding of cystic fibrosis on the foundation of ABC transporter structures

AUTHOR(S)
Juan Mendoza; Philip Thomas
PUB. DATE
December 2007
SOURCE
Journal of Bioenergetics & Biomembranes;Dec2007, Vol. 39 Issue 5/6, p499
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Abstract  Cystic fibrosis (CF) is a fatal disease affecting the lungs and digestive system by impairment of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). While over 1000 mutations in CFTR have been associated with CF, the majority of cases are linked to the deletion of phenylalanine 508 (ΔF508). F508 is located in the first nucleotide binding domain (NBD1) of CFTR. This mutation is sufficient to impair the trafficking of CFTR to the plasma membrane and, thus, its function. As an ABC transporter, recent structural data from the family provide a framework on which to consider the effect of the ΔF508 mutation on CFTR. There are fifty-seven known structures of ABC transporters and domains thereof. Only six of these structures are of the intact transporters. In addition, modern bioinformatic tools provide a wealth of sequence and structural information on the family. We will review the structural information from the RCSB structure repository and sequence databases of the ABC transporters. The available structural information was used to construct a model for CFTR based on the ABC transporter homologue, Sav1866, and provide a context for understanding the molecular pathology of Cystic Fibrosis.
ACCESSION #
28694715

 

Related Articles

  • Advances in Cell and Gene-based Therapies for Cystic Fibrosis Lung Disease. Oakland, Mayumi; Sinn, Patrick L; McCray Jr, Paul B // Molecular Therapy;Jun2012, Vol. 20 Issue 6, p1108 

    Cystic fibrosis (CF) is a disease characterized by airway infection, inflammation, remodeling, and obstruction that gradually destroy the lungs. Direct delivery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene to airway epithelia may offer advantages, as the tissue is...

  • The Mutation Spectrum of the CFTR Gene in Cystic Fibrosis Patients from Bashkortostan. Korytina, G.F.; Viktorova, T.V.; Ivashchenko, T.E.; Baranov, V.S.; Khusnutdinova, E.K. // Molecular Biology;Jan/Feb2003, Vol. 37 Issue 1, p56 

    Mutations of CFTR were studied in patients with cystic fibrosis (CF) from Bashkortostan. In total, 15 mutations were observed and 51% of all mutant alleles identified. The most diagnostically significant mutations were delF508 (33.8%), 394delTT (3.52%), CFTRdele2,3(21kb) (1.41%), R334W (1.41%),...

  • Assessment of CF lung disease using motion corrected PROPELLER MRI: a comparison with CT. Ciet, Pierluigi; Serra, Goffredo; Bertolo, Silvia; Spronk, Sandra; Ros, Mirco; Fraioli, Francesco; Quattrucci, Serena; Assael, M.; Catalano, Carlo; Pomerri, Fabio; Tiddens, Harm.; Morana, Giovanni; Assael, M Baroukh; Tiddens, Harm A W M // European Radiology;Mar2016, Vol. 26 Issue 3, p780 

    Objectives: To date, PROPELLER MRI, a breathing-motion-insensitive technique, has not been assessed for cystic fibrosis (CF) lung disease. We compared this technique to CT for assessing CF lung disease in children and adults.Methods: Thirty-eight stable CF patients...

  • Therapeutic approaches to cystic fibrosis: Memorandum from a joint WHO/ICF(M)A meeting.  // Bulletin of the World Health Organization;1994, Vol. 72 Issue 3, p341 

    Cystic fibrosis is one of the commonest genetic diseases among Caucasians and represents an important cause of suffering and death among children and adults. In the past two decades marked prolongation of the life of patients with cystic fibrosis has been achieved as the result of improved...

  • Novel Pharmaceutical Approaches for Treating Patients with Cystic Fibrosis. Saeed, Z.; Wojewodka, G.; Marion, D.; Guilbault, C.; Radzioch, D. // Current Pharmaceutical Design;Nov2007, Vol. 13 Issue 31, p3252 

    Before the cloning of the CFTR gene in 1989, there were relatively few treatment options for the many phenotypes associated with cystic fibrosis (CF). The advancement of research in areas such as immunology, molecular biology and pharmacology have provided new insights into the mechanism and...

  • Crystal structures of Burkholderia cenocepacia dihydropteroate synthase in the apo-form and complexed with the product 7,8-dihydropteroate. Morgan, Rachel E.; Batot, Gaëlle O.; Dement, Jennifer M.; Rao, Vincenzo A.; Eadsforth, Thomas C.; Hunter, William N. // BMC Structural Biology;2011, Vol. 11 Issue 1, p21 

    Background: The enzyme dihydropteroate synthase (DHPS) participates in the de novo synthesis of folate cofactors by catalyzing the formation of 7,8-dihydropteroate from condensation of p-aminobenzoic acid with 6-hydroxymethyl-7,8-dihydropteroate pyrophosphate. DHPS is absent from humans, who...

  • Modeling the Conformational Changes Underlying Channel Opening in CFTR. Rahman, Kazi S.; Cui, Guiying; Harvey, Stephen C.; McCarty, Nael A. // PLoS ONE;Sep2013, Vol. 8 Issue 9, p1 

    Mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator protein (CFTR) cause cystic fibrosis (CF), the most common life-shortening genetic disease among Caucasians. Although general features of the structure of CFTR have been predicted from homology models, the...

  • A disease called 'sixty-five roses'.  // Nature Structural Biology;Dec2002, Vol. 9 Issue 12, p887 

    Provides information on cystic fibrosis (CF). Cause of CF; Increase in efforts to educate the public about preventing CF; Initial screen for CF.

  • CYSTIC FIBROSIS NO LONGER A FATAL DISEASE. Braverman, Jane // Exceptional Parent;Nov2001, Vol. 31 Issue 11, p87 

    Provides information on cystic fibrosis. Background on the disease; Life expectancies of patients; Diagnosis of the illness; Treatment of the disease.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics